XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment, Geographic and Other Revenue Information | 9 Months Ended
--- | ---
Oct. 02, 2022
Segment Reporting [Abstract] |
Segment, Geographic and Other Revenue Information | Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two operating segments, Biopharma and PC1, which are each led by a single manager. Biopharma is the only reportable segment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&D services from WRDM and GPD. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. After the organizational changes in the third quarter of 2022 (see Note 1A), the new commercial structure within Biopharma is designed to better support and optimize performance across three broad therapeutic areas: •Primary Care consists of the former Internal Medicine and Vaccines product portfolios, as well as COVID-19 products and potential future mRNA products. •Specialty Care consists of the former Inflammation & Immunology, Rare Disease and Hospital (excluding Paxlovid) product portfolios. •Oncology consists of the former Oncology product portfolio. Other Costs and Business Activities––Certain pre-tax costs are not allocated to our operating segment results, such as costs included in Other business activities that are associated with: (i) R&D and medical expenses managed by our WRDM and GPD organizations; (ii) corporate enabling functions and other corporate costs; (iii) overhead costs primarily associated with our manufacturing operations; and (iv) our share of earnings from Haleon/the Consumer Healthcare JV. Additionally, all amortization of intangible assets, acquisition-related items, and certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, are not allocated to our operating segment results. Beginning in the first quarter of 2022, acquisition-related items may now include purchase accounting impacts that previously were included as part of a reconciling item entitled “Purchase accounting adjustments” that we no longer separately present, such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. The operating results of PC1 are included in Other business activities. Segment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $195 billion as of October 2, 2022 and $181 billion as of December 31, 2021. Selected Income Statement Information
The following provides selected income statement information by reportable segment:
|  | Three Months Ended |  | Nine Months Ended
|  | Revenues |  | Earnings(a) |  | Revenues |  | Earnings(a)
(MILLIONS) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021
Reportable Segment: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biopharma |  | $ | 22,319 |  |  | $ | 23,513 |  |  | $ | 14,665 |  |  | $ | 11,848 |  |  | $ | 75,066 |  |  | $ | 56,101 |  |  | $ | 45,222 |  |  | $ | 29,952 |
Other business activities(b) |  | 319 |  |  | 521 |  |  | (4,007) |  |  | (3,303) |  |  | 974 |  |  | 1,348 |  |  | (9,820) |  |  | (7,778) |
Reconciling Items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of intangible assets |  | — |  |  | — |  |  | (822) |  |  | (980) |  |  | — |  |  | — |  |  | (2,478) |  |  | (2,778) |
Acquisition-related items |  | — |  |  | — |  |  | (62) |  |  | (41) |  |  | — |  |  | — |  |  | (331) |  |  | (14) |
Certain significant items(c) |  | — |  |  | — |  |  | (773) |  |  | 318 |  |  | — |  |  | — |  |  | (3,095) |  |  | 1,102 |
|  | $ | 22,638 |  |  | $ | 24,035 |  |  | $ | 9,001 |  |  | $ | 7,843 |  |  | $ | 76,040 |  |  | $ | 57,450 |  |  | $ | 29,498 |  |  | $ | 20,484 |
(a)I ncome from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $112 million in the third quarter of 2022 and $38 million in the third quarter of 2021, and $237 million in the first nine months of 2022 and $127 million in the first nine months of 2021. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $105 million of costs for the first six months of 2022, $57 million of costs in the third quarter of 2021 and $153 million of costs in the first nine months of 2021 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation. (b)Other business activities include revenues and costs associated with PC1 and costs that we do not allocate to our operating segments, per above, including acquired IPR&D expenses in the periods presented. In the third quarter and first nine months of 2022, earnings include $426 million of acquired IPR&D expenses for an upfront payment related to the closing of the acquisition of ReViral, as well as a charge to Cost of sales of approximately $400 million related to excess raw materials for Paxlovid. Earnings in the first nine months of 2022 also include write-offs to Cost of sales of inventory, related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used, of $516 million. In the third quarter and first nine months of 2021, earnings include $706 million of acquired IPR&D expenses associated with our collaboration with Arvinas. (c)Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2022 includes, among other items: (i) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $701 million ($344 million recorded in Selling, informational and administrative expenses and the remaining amounts primarily recorded in Restructuring charges and certain acquisition-related costs). Earnings in the first nine months of 2021 includes, among other items: (i) net gains on equity securities of $1.6 billion recorded in Other (income)/deductions––net and (ii) actuarial valuation and other pension and postretirement plan gains of $932 million recorded in Other (income)/deductions––net, partially offset by (iii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.1 billion ($310 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs). Earnings in the third quarter of 2021 includes, among other items: (i) actuarial valuation and other pension and postretirement plan gains of $899 million recorded in Other (income)/deductions––net, partially offset by (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $823 million ($150 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs). For additional information, see Notes 3 and 4. B. Geographic Information
The following summarizes revenues by geographic area:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS) |  | October 2, 2022 |  | October 3, 2021 |  | % Change |  | October 2, 2022 |  | October 3, 2021 |  | % Change
United States |  | $ | 13,851 |  |  | $ | 7,020 |  |  | 97 |  |  | $ | 33,991 |  |  | $ | 22,066 |  |  | 54 |
Developed Europe |  | 3,136 |  |  | 6,221 |  |  | (50) |  |  | 14,705 |  |  | 13,836 |  |  | 6 |
Developed Rest of World |  | 2,351 |  |  | 4,498 |  |  | (48) |  |  | 10,671 |  |  | 8,617 |  |  | 24 |
Emerging Markets |  | 3,300 |  |  | 6,296 |  |  | (48) |  |  | 16,673 |  |  | 12,930 |  |  | 29 |
Revenues |  | $ | 22,638 |  |  | $ | 24,035 |  |  | (6) |  |  | $ | 76,040 |  |  | $ | 57,450 |  |  | 32 |
C. Other Revenue Information Significant Customers––For information on our significant wholesale customers, see Note 17C in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented 38% and 27% of total revenues for the three and nine months ended October 2, 2022, respectively, and primarily represent sales of Paxlovid and Comirnaty. Accounts receivable from the U.S. government represented 44% of total trade accounts receivable as of October 2, 2022, and primarily relate to sales of Paxlovid and Comirnaty. Significant Product Revenues The following provides detailed revenue information for several of our major products:
(MILLIONS) |  |  |  | Three Months Ended |  | Nine Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | Oct. 2, 2022 |  | Oct. 3, 2021 |  | Oct. 2, 2022 |  | Oct. 3, 2021
TOTAL REVENUES(a) |  |  |  | $ | 22,638 |  |  | $ | 24,035 |  |  | $ | 76,040 |  |  | $ | 57,450 |
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a), (b) |  | $ | 22,319 |  |  | $ | 23,513 |  |  | $ | 75,066 |  |  | $ | 56,101 |
Primary Care |  |  |  | $ | 15,846 |  |  | $ | 16,680 |  |  | $ | 55,676 |  |  | $ | 35,804 |
Comirnaty direct sales and alliance revenues(c) |  | Active immunization to prevent COVID-19 |  | 4,402 |  |  | 12,977 |  |  | 26,477 |  |  | 24,277 |
Paxlovid |  | COVID-19 infection (high risk population) |  | 7,514 |  |  | — |  |  | 17,099 |  |  | — |
Eliquis alliance revenues and direct sales |  | Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism |  | 1,464 |  |  | 1,346 |  |  | 5,001 |  |  | 4,470 |
Prevnar family(d) |  | Pneumococcal disease |  | 1,607 |  |  | 1,447 |  |  | 4,601 |  |  | 3,971 |
Premarin family |  | Symptoms of menopause |  | 110 |  |  | 148 |  |  | 327 |  |  | 420 |
Nimenrix |  | Meningococcal ACWY disease |  | 79 |  |  | 51 |  |  | 221 |  |  | 145 |
BMP2 |  | Development of bone and cartilage |  | 58 |  |  | 71 |  |  | 201 |  |  | 186 |
FSME-IMMUN/TicoVac |  | Tick-borne encephalitis disease |  | 67 |  |  | 47 |  |  | 177 |  |  | 161 |
Toviaz |  | Overactive bladder |  | 30 |  |  | 56 |  |  | 130 |  |  | 174 |
Trumenba |  | Meningococcal B disease |  | 60 |  |  | 52 |  |  | 108 |  |  | 102 |
Chantix/Champix |  | An aid to smoking cessation treatment in adults 18 years of age or older |  | 4 |  |  | 7 |  |  | 8 |  |  | 409 |
All other Primary Care |  | Various |  | 451 |  |  | 479 |  |  | 1,326 |  |  | 1,490 |
Specialty Care |  |  |  | $ | 3,404 |  |  | $ | 3,749 |  |  | $ | 10,267 |  |  | $ | 11,205 |
Vyndaqel/Vyndamax |  | ATTR-CM and polyneuropathy |  | 602 |  |  | 501 |  |  | 1,766 |  |  | 1,454 |
Xeljanz |  | RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis |  | 502 |  |  | 610 |  |  | 1,304 |  |  | 1,734 |
Enbrel (Outside the U.S. and Canada) |  | RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis |  | 230 |  |  | 283 |  |  | 767 |  |  | 888 |
Sulperazon |  | Bacterial infections |  | 178 |  |  | 181 |  |  | 598 |  |  | 515 |
Inflectra |  | Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis |  | 131 |  |  | 172 |  |  | 403 |  |  | 485 |
Ig Portfolio(e) |  | Various |  | 124 |  |  | 99 |  |  | 356 |  |  | 311 |
BeneFIX |  | Hemophilia B |  | 99 |  |  | 104 |  |  | 325 |  |  | 328 |
Zavicefta |  | Bacterial infections |  | 98 |  |  | 107 |  |  | 302 |  |  | 306 |
Genotropin |  | Replacement of human growth hormone |  | 90 |  |  | 95 |  |  | 261 |  |  | 284 |
Zithromax |  | Bacterial infections |  | 71 |  |  | 66 |  |  | 250 |  |  | 198 |
Medrol |  | Anti-inflammatory glucocorticoid |  | 79 |  |  | 109 |  |  | 235 |  |  | 320 |
Fragmin |  | Treatment/prevention of venous thromboembolism |  | 60 |  |  | 74 |  |  | 202 |  |  | 223 |
Somavert |  | Acromegaly |  | 70 |  |  | 70 |  |  | 202 |  |  | 203 |
Refacto AF/Xyntha |  | Hemophilia A |  | 58 |  |  | 69 |  |  | 188 |  |  | 235 |
Vfend |  | Fungal infections |  | 51 |  |  | 51 |  |  | 171 |  |  | 204 |
All other Anti-infectives |  | Various |  | 374 |  |  | 455 |  |  | 1,123 |  |  | 1,384 |
All other Specialty Care |  | Various |  | 586 |  |  | 702 |  |  | 1,816 |  |  | 2,134 |
Oncology |  |  |  | $ | 3,070 |  |  | $ | 3,085 |  |  | $ | 9,124 |  |  | $ | 9,091 |
Ibrance |  | HR-positive/HER2-negative metastatic breast cancer |  | 1,283 |  |  | 1,381 |  |  | 3,841 |  |  | 4,039 |
Xtandi alliance revenues |  | mCRPC, nmCRPC, mCSPC |  | 320 |  |  | 309 |  |  | 878 |  |  | 879 |
Inlyta |  | Advanced RCC |  | 252 |  |  | 256 |  |  | 760 |  |  | 742 |
Zirabev |  | Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer |  | 146 |  |  | 96 |  |  | 432 |  |  | 311 |
Bosulif |  | Philadelphia chromosome–positive chronic myelogenous leukemia |  | 141 |  |  | 136 |  |  | 425 |  |  | 395 |
Xalkori |  | ALK-positive and ROS1-positive advanced NSCLC |  | 118 |  |  | 116 |  |  | 362 |  |  | 371 |
Ruxience |  | Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis |  | 120 |  |  | 124 |  |  | 357 |  |  | 343 |
(MILLIONS) |  |  |  | Three Months Ended |  | Nine Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | Oct. 2, 2022 |  | Oct. 3, 2021 |  | Oct. 2, 2022 |  | Oct. 3, 2021
Retacrit |  | Anemia |  | 87 |  |  | 110 |  |  | 308 |  |  | 322 |
Sutent |  | Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor |  | 75 |  |  | 142 |  |  | 287 |  |  | 537 |
Lorbrena |  | ALK-positive metastatic NSCLC |  | 99 |  |  | 67 |  |  | 247 |  |  | 193 |
Bavencio alliance revenues |  | Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC |  | 73 |  |  | 54 |  |  | 198 |  |  | 122 |
Aromasin |  | Post-menopausal early and advanced breast cancer |  | 66 |  |  | 56 |  |  | 187 |  |  | 159 |
Besponsa |  | Relapsed or refractory B-cell acute lymphoblastic leukemia |  | 55 |  |  | 50 |  |  | 164 |  |  | 145 |
Braftovi |  | In combination with Mektovi for metastatic melanoma in patients with a BRAF V600E/K mutation and, in combination with Erbitux® (cetuximab)(f), for the treatment of BRAF V600E -mutant mCRC after prior therapy |  | 58 |  |  | 47 |  |  | 156 |  |  | 136 |
Trazimera |  | HER-positive breast cancer and metastatic stomach cancers |  | 51 |  |  | 45 |  |  | 149 |  |  | 131 |
Mektovi |  | In combination with Braftovi for metastatic melanoma in patients with a BRAF V600E/K mutation |  | 45 |  |  | 41 |  |  | 129 |  |  | 112 |
All other Oncology |  | Various |  | 80 |  |  | 53 |  |  | 243 |  |  | 155 |
PFIZER CENTREONE(b) |  | $ | 319 |  |  | $ | 521 |  |  | $ | 974 |  |  | $ | 1,348 |
Total Alliance revenues included above |  | $ | 1,689 |  |  | $ | 2,068 |  |  | $ | 6,320 |  |  | $ | 5,718 |
(a)On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See Note 1A. (b)See Note 1A for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7 million and $108 million for the third quarter and the first nine months of 2022, respectively, and $187 million and $274 million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio. (c)Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. (d)Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult). (e)Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig. (f)Erbitux® is a registered trademark of ImClone LLC. Remaining Performance Obligations––Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $22 billion as of October 2, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $9 billion in 2022, $13 billion in 2023 and $200 million in 2024. Remaining performance obligations are based on foreign exchange rates as of the end of the third quarter of 2022 and exclude arrangements with an original expected contract duration of less than one year. Deferred Revenues––Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues related to Comirnaty and Paxlovid total $6.2 billion as of October 2, 2022, with $6.1 billion and $126 million recorded in current and noncurrent liabilities, respectively. The deferred revenues related to Comirnaty total $3.3 billion as of December 31, 2021, with $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively. There were no deferred revenues associated with Paxlovid as of December 31, 2021. The increase in Comirnaty and Paxlovid deferred revenues during the first nine months of 2022 was primarily the result of additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, less amounts recognized in Revenues as we delivered the products to our customers and the impact of foreign exchange. During the third quarter and first nine months of 2022, we recognized revenue of $68 million and $2.5 billion, respectively, that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of October 2, 2022 will be recognized in Revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in Revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Revenues in the last three months of 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of October 2, 2022 or December 31, 2021.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration